Polysaccharides from Chinese Herbal Lycium barbarum Induced Systemic and Local Immune Responses in H22 Tumor-Bearing Mice
暂无分享,去创建一个
S. Luo | X. Lai | Lian Zhou | Xia Luo | Lian Zhou | Xiaoping Lai | Shuang Luo | Xiangliang Deng | Xia Luo | Minghua Hu | Fangli Ma | Yuanyuan Wang | Minghua Hu | Fangli Ma | Xiangliang Deng | Yuanyuan Wang
[1] Ana Cumano,et al. CD25+ CD4+ T Cells Regulate the Expansion of Peripheral CD4 T Cells Through the Production of IL-101 , 2001, The Journal of Immunology.
[2] S. Luo,et al. Antitumor activity of Lycium barbarum polysaccharides with different molecular weights: an in vitro and in vivo study , 2017, Food & nutrition research.
[3] T. Oshikiri,et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma , 2006, British Journal of Cancer.
[4] Y. Li,et al. PD-1+ CD8+ T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients , 2014, British Journal of Cancer.
[5] Gisen Kim,et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis , 2009, Nature Immunology.
[6] F. Ghiringhelli,et al. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer , 2011, Cancer Immunology, Immunotherapy.
[7] Xia Luo,et al. Effects of ceftriaxone induced intestinal dysbacteriosis on lymphocytes in different tissues in mice. , 2016, Immunobiology.
[8] F. Wang,et al. Characterization of Lycium barbarum polysaccharide and its effect on human hepatoma cells. , 2013, International journal of biological macromolecules.
[9] M. Smyth,et al. CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer1 , 2006, The Journal of Immunology.
[10] Liang Zhou,et al. Neuroprotective effects of Lycium barbarum polysaccharides in lipopolysaccharide-induced BV2 microglial cells. , 2013, Molecular medicine reports.
[11] Yun Chen,et al. Attenuated Listeria monocytogenes as a cancer vaccine vector for the delivery of CD24, a biomarker for hepatic cancer stem cells , 2014, Cellular and Molecular Immunology.
[12] W. Han,et al. Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy , 2016, Journal of the National Cancer Institute.
[13] M. Neurath,et al. Cutting Edge: TGF-β Signaling Is Required for the In Vivo Expansion and Immunosuppressive Capacity of Regulatory CD4+CD25+ T Cells1 , 2004, The Journal of Immunology.
[14] Jie Zhu,et al. Lycium barbarum polysaccharides regulate phenotypic and functional maturation of murine dendritic cells , 2007, Cell biology international.
[15] T. Whiteside,et al. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer , 2005, British Journal of Cancer.
[16] Thomas M. Schmitt,et al. Re‐adapting T cells for cancer therapy: from mouse models to clinical trials , 2014, Immunological reviews.
[17] Yong Zhao,et al. Alterations of peripheral CD4+CD25+Foxp3+ T regulatory cells in mice with STZ-induced diabetes , 2011, Cellular and Molecular Immunology.
[18] Shumei Yan,et al. PD-L1 Expression Is Associated with FOXP3+ Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis , 2017, Journal of Cancer.
[19] Jinliang Peng,et al. Alleviation of the acute doxorubicin-induced cardiotoxicity by Lycium barbarum polysaccharides through the suppression of oxidative stress. , 2011, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[20] Zhiyong Wu,et al. Prognostic Significance of Tumor-infiltrating CD8+ or CD3+ T Lymphocytes and Interleukin-2 Expression in Radically Resected Non-small Cell Lung Cancer , 2015, Chinese medical journal.
[21] Wen-xia Zhou,et al. Lycium barbarum polysaccharide LBPF4-OL may be a new Toll-like receptor 4/MD2-MAPK signaling pathway activator and inducer. , 2014, International immunopharmacology.
[22] A. Jemal,et al. Global Cancer Statistics , 2011 .
[23] D. Mullins,et al. Tumor cell‐derived TGF‐β and IL‐10 dysregulate paclitaxel‐induced macrophage activation , 2001, Journal of leukocyte biology.
[24] L. Gan,et al. Immunomodulation and antitumor activity by a polysaccharide-protein complex from Lycium barbarum. , 2004, International immunopharmacology.
[25] R. G. van der Most,et al. Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies , 2012, British Journal of Cancer.
[26] S. Akira,et al. Macrophages and Myeloid Dendritic Cells, but Not Plasmacytoid Dendritic Cells, Produce IL-10 in Response to MyD88- and TRIF-Dependent TLR Signals, and TLR-Independent Signals1 , 2006, The Journal of Immunology.
[27] Zhenguang Liu,et al. Simple nanoliposomes encapsulating Lycium barbarum polysaccharides as adjuvants improve humoral and cellular immunity in mice , 2017, International journal of nanomedicine.
[28] V. Engelhard,et al. Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. , 2015, Advances in cancer research.
[29] Han-Wei Lin,et al. Depletion of Regulatory T Lymphocytes Reverses the Imbalance between Pro- and Anti-Tumor Immunities via Enhancing Antigen-Specific T Cell Immune Responses , 2012, PloS one.
[30] S. Chan,et al. Activation of T lymphocytes by polysaccharide-protein complex from Lycium barbarum L. , 2008, International immunopharmacology.
[31] Ji Luo,et al. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.
[32] B. Zhu,et al. T-cell exhaustion in the tumor microenvironment , 2015, Cell Death and Disease.
[33] D. Cohen,et al. CD5 plays an inhibitory role in the suppressive function of murine CD4(+) CD25(+) T(reg) cells. , 2008, Immunology letters.
[34] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[35] Chun-Hong Zhao,et al. Synergistic immunotherapeutic effects of Lycium barbarum polysaccharide and interferon-α2b on the murine Renca renal cell carcinoma cell line in vitro and in vivo , 2015, Molecular medicine reports.
[36] H. Nawata,et al. TGF-β1 Plays an Important Role in the Mechanism of CD4+CD25+ Regulatory T Cell Activity in Both Humans and Mice , 2004, The Journal of Immunology.
[37] Xiao-rui Zhang,et al. Immune activities comparison of polysaccharide and polysaccharide-protein complex from Lycium barbarum L. , 2014, International journal of biological macromolecules.
[38] Tao-Tao Liu,et al. Hepatocellular Carcinoma Cells Induce Regulatory T Cells and Lead to Poor Prognosis via Production of Transforming Growth Factor-β1 , 2016, Cellular Physiology and Biochemistry.
[39] J. Myśliwska,et al. CD4+CD25+ T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans-impact of immunosenescence. , 2006, Clinical immunology.
[40] S. Ansell,et al. Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. , 2006, Cancer research.
[41] N. Mount,et al. Genetically modified T cells in cancer therapy: opportunities and challenges , 2015, Disease Models & Mechanisms.
[42] D. Fowell,et al. CTLA‐4 is required by CD4+CD25+ Treg to control CD4+ T‐cell lymphopenia‐induced proliferation , 2009, European journal of immunology.
[43] M. Werner,et al. Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes , 2009, British Journal of Cancer.